253 filings
Page 5 of 13
8-K
19ak3ib 9wwx0
30 Mar 21
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
6:01am
8-K
jdkfo8moj4
8 Mar 21
Regulation FD Disclosure
8:38am
S-8
9jx kk9uiu0eofhu6
1 Mar 21
Registration of securities for employees
4:31pm
8-K
zdnx3jhtgdgo06kqic4l
25 Feb 21
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
4:10pm
8-K
s3fg ezcba
28 Dec 20
Regulation FD Disclosure
8:35am
8-K
zpzs2
9 Nov 20
Cara Therapeutics Reports Third Quarter 2020 Financial Results
4:10pm
8-K
n8djm
20 Oct 20
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
6:30am
8-K
8x6te9zkrpgur 91cif
1 Oct 20
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
5:17pm
8-K/A
3c7fg9g8
11 Aug 20
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
26o8495 lahp5m7
10 Aug 20
Cara Therapeutics Reports Second Quarter 2020 Financial Results
4:10pm
8-K
3prlo2
30 Jun 20
Departure of Directors or Certain Officers
7:18am
8-K
3akov3 s5yaaoaufj
17 Jun 20
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with KARE Phase 2 Trial Design
7:11am
8-K
o5fha4
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
w3hu9j
11 May 20
Cara Therapeutics Reports First Quarter 2020 Financial Results
4:10pm
DEFA14A
7e6g5hiand6dbqwe
22 Apr 20
Additional proxy soliciting materials
4:32pm